FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093582005> ?p ?o ?g. }

• W2093582005 endingPage "5686" @default.
• W2093582005 startingPage "5673" @default.
• W2093582005 abstract "HIV-1 gp120 binds the primary receptor CD4. Recently, a plethora of broadly neutralizing antibodies to the gp120 CD4-binding site (CD4bs) validated this region as a target for immunogen design. Here, we asked if modified HIV-1 envelope glycoproteins (Env) designed to increase CD4 recognition might improve recognition by CD4bs neutralizing antibodies and more efficiently elicit such reactivities. We also asked if CD4bs stabilization, coupled with altering the Env format (monomer to trimer or cross-clade), might better elicit neutralizing antibodies by focusing the immune response on the functionally conserved CD4bs. We produced monomeric and trimeric Envs stabilized by mutations within the gp120 CD4bs cavity (pocket-filling; PF2) or by appending heterologous trimerization motifs to soluble Env ectodomains (gp120/gp140). Recombinant glycoproteins were purified to relative homogeneity, and ligand binding properties were analyzed by ELISA, surface plasmon resonance, and isothermal titration microcalorimetry. In some formats, the PF2 substitutions increased CD4 affinity, and importantly, PF2-containing proteins were better recognized by the broadly neutralizing CD4bs mAbs, VRC01 and VRC-PG04. Based on this analysis, we immunized selected Env variants into rabbits using heterologous or homologous regimens. Analysis of the sera revealed that homologous inoculation of the PF2-containing, variable region-deleted YU2 gp120 trimers (ΔV123/PF2-GCN4) more rapidly elicited CD4bs-directed neutralizing antibodies compared with other regimens, whereas homologous trimers elicited increased neutralization potency, mapping predominantly to the gp120 third major variable region (V3). These results suggest that some engineered Env proteins may more efficiently direct responses toward the conserved CD4bs and be valuable to elicit antibodies of greater neutralizing capacity. HIV-1 gp120 binds the primary receptor CD4. Recently, a plethora of broadly neutralizing antibodies to the gp120 CD4-binding site (CD4bs) validated this region as a target for immunogen design. Here, we asked if modified HIV-1 envelope glycoproteins (Env) designed to increase CD4 recognition might improve recognition by CD4bs neutralizing antibodies and more efficiently elicit such reactivities. We also asked if CD4bs stabilization, coupled with altering the Env format (monomer to trimer or cross-clade), might better elicit neutralizing antibodies by focusing the immune response on the functionally conserved CD4bs. We produced monomeric and trimeric Envs stabilized by mutations within the gp120 CD4bs cavity (pocket-filling; PF2) or by appending heterologous trimerization motifs to soluble Env ectodomains (gp120/gp140). Recombinant glycoproteins were purified to relative homogeneity, and ligand binding properties were analyzed by ELISA, surface plasmon resonance, and isothermal titration microcalorimetry. In some formats, the PF2 substitutions increased CD4 affinity, and importantly, PF2-containing proteins were better recognized by the broadly neutralizing CD4bs mAbs, VRC01 and VRC-PG04. Based on this analysis, we immunized selected Env variants into rabbits using heterologous or homologous regimens. Analysis of the sera revealed that homologous inoculation of the PF2-containing, variable region-deleted YU2 gp120 trimers (ΔV123/PF2-GCN4) more rapidly elicited CD4bs-directed neutralizing antibodies compared with other regimens, whereas homologous trimers elicited increased neutralization potency, mapping predominantly to the gp120 third major variable region (V3). These results suggest that some engineered Env proteins may more efficiently direct responses toward the conserved CD4bs and be valuable to elicit antibodies of greater neutralizing capacity." @default.
• W2093582005 created "2016-06-24" @default.
• W2093582005 creator A5022155820 @default.
• W2093582005 creator A5024087236 @default.
• W2093582005 creator A5027746837 @default.
• W2093582005 creator A5030740162 @default.
• W2093582005 creator A5037123473 @default.
• W2093582005 creator A5048710008 @default.
• W2093582005 creator A5064359646 @default.
• W2093582005 creator A5071657202 @default.
• W2093582005 creator A5083386185 @default.
• W2093582005 creator A5087833005 @default.
• W2093582005 date "2012-02-01" @default.
• W2093582005 modified "2023-10-18" @default.
• W2093582005 title "Biochemically Defined HIV-1 Envelope Glycoprotein Variant Immunogens Display Differential Binding and Neutralizing Specificities to the CD4-binding Site" @default.
• W2093582005 cites W1656939007 @default.
• W2093582005 cites W1916975350 @default.
• W2093582005 cites W1965019797 @default.
• W2093582005 cites W1971777539 @default.
• W2093582005 cites W1974543288 @default.
• W2093582005 cites W1980696330 @default.
• W2093582005 cites W1981164507 @default.
• W2093582005 cites W1981440980 @default.
• W2093582005 cites W1981644527 @default.
• W2093582005 cites W1981726195 @default.
• W2093582005 cites W1989035987 @default.
• W2093582005 cites W1990798903 @default.
• W2093582005 cites W1993366615 @default.
• W2093582005 cites W1994609426 @default.
• W2093582005 cites W1995355944 @default.
• W2093582005 cites W1996024432 @default.
• W2093582005 cites W1996183144 @default.
• W2093582005 cites W2005780220 @default.
• W2093582005 cites W2006483986 @default.
• W2093582005 cites W2009151161 @default.
• W2093582005 cites W2013330052 @default.
• W2093582005 cites W2017551575 @default.
• W2093582005 cites W2023422628 @default.
• W2093582005 cites W2025694212 @default.
• W2093582005 cites W2033669661 @default.
• W2093582005 cites W2043858104 @default.
• W2093582005 cites W2044465251 @default.
• W2093582005 cites W2049496803 @default.
• W2093582005 cites W2049836668 @default.
• W2093582005 cites W2051005349 @default.
• W2093582005 cites W2059474578 @default.
• W2093582005 cites W2060620553 @default.
• W2093582005 cites W2063701397 @default.
• W2093582005 cites W2064609137 @default.
• W2093582005 cites W2080089116 @default.
• W2093582005 cites W2084310667 @default.
• W2093582005 cites W2089766500 @default.
• W2093582005 cites W2098781795 @default.
• W2093582005 cites W2099381548 @default.
• W2093582005 cites W2102044579 @default.
• W2093582005 cites W2105841559 @default.
• W2093582005 cites W2110499527 @default.
• W2093582005 cites W2110669507 @default.
• W2093582005 cites W2110679986 @default.
• W2093582005 cites W2113236498 @default.
• W2093582005 cites W2113282092 @default.
• W2093582005 cites W2118274231 @default.
• W2093582005 cites W2119711460 @default.
• W2093582005 cites W2123602858 @default.
• W2093582005 cites W2124935744 @default.
• W2093582005 cites W2125400731 @default.
• W2093582005 cites W2125488268 @default.
• W2093582005 cites W2126067457 @default.
• W2093582005 cites W2126095200 @default.
• W2093582005 cites W2131376910 @default.
• W2093582005 cites W2135151522 @default.
• W2093582005 cites W2137939749 @default.
• W2093582005 cites W2143572016 @default.
• W2093582005 cites W2145909184 @default.
• W2093582005 cites W2146704167 @default.
• W2093582005 cites W2150090112 @default.
• W2093582005 cites W2156557297 @default.
• W2093582005 cites W2159211452 @default.
• W2093582005 cites W2163208301 @default.
• W2093582005 cites W2169897314 @default.
• W2093582005 cites W2171488159 @default.
• W2093582005 cites W2171536421 @default.
• W2093582005 cites W2318162832 @default.
• W2093582005 cites W4235232179 @default.
• W2093582005 cites W4237410627 @default.
• W2093582005 doi "https://doi.org/10.1074/jbc.m111.317776" @default.
• W2093582005 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3285340" @default.
• W2093582005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22167180" @default.
• W2093582005 hasPublicationYear "2012" @default.
• W2093582005 type Work @default.
• W2093582005 sameAs 2093582005 @default.
• W2093582005 citedByCount "53" @default.
• W2093582005 countsByYear W20935820052012 @default.
• W2093582005 countsByYear W20935820052013 @default.
• W2093582005 countsByYear W20935820052014 @default.
• W2093582005 countsByYear W20935820052015 @default.
• W2093582005 countsByYear W20935820052016 @default.
• W2093582005 countsByYear W20935820052017 @default.

• next